Elevai Labs Inc. announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity?s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. The members of Elevai?s new Scientific Advisory Board include: Roger A. Fielding, PhD serves as Team Lead and Senior Scientist of the Nutrition, Exercise Physiology, and Sarcopenia (NEPS) Team at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. He is also Professor of Nutrition at Tufts?

Friedman School of Nutrition Science and Policy, Professor of Medicine at Tufts University School of Medicine and the Associate Director of the Boston Claude D. Pepper Older Americans Independence Center. Dr. Fielding is an internationally known researcher who studies the underlying mechanisms contributing to age-associated decline in skeletal muscle mass, the resultant impact on function, and the potential role of exercise, nutrition, physical activity and other therapies on attenuating this process. He has published over 300 peer-reviewed papers (H-index 115).

Dr. Fielding has a strong record of extramural funding, including support from the NIH, USDA, foundations and industry. He is a Deputy Editor of The Journals of Gerontology Medical Sciences, and Calcified Tissues International and Musculoskeletal Research. He has also served as a reviewer on numerous National Institutes of Health (NIH) study sections and was elected to the NIH/CSR College of Reviewers.

In 2015, Dr. Fielding received the Olof Johnell Science Award from the International Osteoporosis Foundation, and in 2021 he received the Herbert Fleisch Medal from the same organization. Eduardo Grunvald, MD, is a board-certified obesity medicine physician. As Director of the Weight Management Program of the University of California San Diego, Dr. Grunvald evaluates and manages patients through their health- and weight-loss journeys and has extensive experience using medications for weight management.

As a professor in the Department of Medicine, Dr. Grunvald is very active in teaching on topics such as metabolism, weight regulation and the treatment of obesity and weight-related medical conditions. He serves on a national committee working on standardizing obesity education in medical schools. His research interests include anti-obesity medications, obesity medicine education and bariatric surgery.

Dr. Grunvald completed his residency training at the UC San Diego School of Medicine. Dr. Grunvald has served as an advisory board consultant for Novo Nordisk. He earned his medical degree at the University of Washington School of Medicine.

He is board certified in internal medicine and obesity medicine, and is a fellow of the American College of Physicians (FACP). Elevai expects to be recruiting additional distinguished scientific leaders with vast experience in the metabolic and obesity field to join its the Scientific Advisory Board.